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Edited by Lukas HuberAbstract Angiotensin II (Ang II) induces a prominent and sus-
tained nitration and activation of ERK1/2 in rat vascular smooth
muscle cells, both mediated via AT1 receptor. Nitration and acti-
vation was also shown for recombinant non-activated extracellu-
lar signal-regulated kinase (ERK) and MEK. Nitration and
phosphorylation of ERK1/2 by Ang II was signiﬁcantly inhibited
by NAD(P)H inhibitors and scavengers of oxygen and nitrogen
reactive species and completely blocked by a selective inducible
nitric-oxide synthase inhibitor. MEK inhibitor U0126 did not af-
fect ERK nitration but completely blocked activation. These
data indicate that Ang II nitrates and activates ERK1/2 via a
reactive species-sensitive pathway.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Angiotensin II (Ang II), a multifunctional hormone, acti-
vates mitogen-activated protein kinase (MAPK) pathways at
various intracellular levels [1,2]. It induces phosphorylation
of three major classes of the family of MAPKs: ERK1/2,
JNK, and p38 in cultured vascular smooth muscle cells
(VSMC) [1–3]. Ang II speciﬁcally activates NAD(P)H oxidase
to produce reactive oxygen species (ROS) such as superoxide
ðO2 Þ and H2O2 in VSMC [3,4]. In addition, Ang II stimulates
production of reactive nitrogen species such as NO and per-
oxynitrite (ONOO) [5] which occurs most probably via
activation of inducible nitric-oxide synthase (iNOS) known
to produce ONOO in vivo [6]. Most of the mitogenic and
growth-promoting eﬀects in VSMC Ang II exerts via Ang II
type 1 receptors (AT1) [1,2].Abbreviations: Ang II, angiotensin II; MAPK, mitogen-activated
protein kinase; ERK, extracellular signal-regulated kinase; VSMC,
vascular smooth muscle cells; NO, nitric oxide; O2 superoxide anion;
ONOO, peroxynitrite; SIN-1, 3-morpholinosydnonimine hydrochlo-
ride; DPI, diphenylene iodonium; L-NAME, nitro-L-arginine-methyl-
ester; AEBSF, 4-(2-aminoethyl) benzenesulfonyl ﬂuoride; MBP,
myelin basic protein
*Corresponding author. Fax: +33 4 76 63 71 78.
E-mail address: serge.bottari@ujf-grenoble.fr (S.P. Bottari).
0014-5793/$30.00  2005 Published by Elsevier B.V. on behalf of the Feder
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tive species such as NO and O2 [3,7]. NO, when present in
cells in micromolar range can compete with superoxide dismu-
tase to scavenge the O2 radical to form ONOO under phys-
iological conditions [8]. ONOO can nitrate tyrosine residues
thus altering the conformation, structure, and catalytic activity
of proteins [9]. Tyrosine nitration impairs phosphorylation of
tyrosine residues of certain enzymes [10,11] while alternatively,
nitration can also stimulate phosphorylation under certain
physiological conditions [12,13]. Furthermore, a major target
for ONOO appears to be the MAPK family. Indeed, ONOO
has been found to activate ERK1/2, JNK, and p38 MAPK di-
rectly [14,15] or via activation of EGFR, Raf-1, and MEK-1
[16] in various cell types. These data suggest a role for tyrosine
nitration by ONOO as a physiological regulator of MAPK
signaling pathways.
In the present study, we investigated the possible nitration of
ERK1/2 upon Ang II treatment and examined the mechanism
of interaction between nitration and activation of the enzyme.2. Materials and methods
2.1. Materials and chemicals
Ang II, 3-morpholinosydnonimine hydrochloride (SIN-1), myrice-
tin, PD123319, CV11974, ebselen, diphenylene iodonium (DPI), and
nitro-L-arginine-methyl-ester (L-NAME) were purchased from Sigma.
4-(2-Aminoethyl) benzenesulfonyl ﬂuoride (AEBSF) was from Upti-
ma, Interchim. 1400W and MEK inhibitor U-0126 were from Acros
Organics and Cell Signaling Technology, respectively.
2.2. Cell culture sample preparation and immunoprecipitation
Rat VSMC were isolated from the thoracic aorta essentially as de-
tailed previously [17]. Cell cultures were maintained under 5% CO2
at 37 C in Dulbeccos modiﬁed Eagles medium (DMEM) containing
10% fetal calf serum and 20 lg/ml of gentamycin. Conﬂuent cells of
passages 3–6 were used for experiments. Protein concentration in cyto-
solic fractions was determined by the Bradford method with bovine
serum albumin as a standard.
For immunoprecipitation, 2–10 lg of anti-ERK, anti-phospho-ERK
or anti-nitrotyrosine antibodies were bound to protein A–agarose
beads and then incubated with 500–1000 lg of total proteins from
cytosolic fraction. The immunoprecipitates were then subjected to
Western immunoblotting.
2.3. Western Immunoblot analysis
For Western blot analysis, samples were subjected to 10% SDS–
polyacrylamide gel electrophoresis and transferred to a nitrocellu-
lose membrane (Millipore). The membranes were immunostained
with mouse monoclonal anti-phospho-ERK, rabbit polyclonal
antisera against nitrotyrosine, anti-phospho-MEK, anti-MEK oration of European Biochemical Societies.
Fig. 1. Time course of Ang II-induced ERK1/2 nitration and
phosphorylation. VSMC were treated with 10 nM Ang II for 0–
60 min. Western blot of ERK immunoprecipitated from the soluble
fractions with anti-ERK antibodies, probed with anti-phospho-ERK
(A) or anti-nitrotyrosine (B) antibodies. Bar graphs are representative
densitometric analyses of ﬁve separate experiments expressed as the
E. Pinzar et al. / FEBS Letters 579 (2005) 5100–5104 5101anti-phospho-myelin basic protein (MBP) antibodies followed by
anti-mouse or anti-rabbit IgG antibody conjugated with horserad-
ish peroxidase. The immunostaining was visualised by enhanced
chemiluminescense (UptiLight HRP blot substrate from Interchim).
2.4. In vitro ERK and MEK phosphorylation kinase assay
Activation of non-activated extracellular signal-regulated kinase
(ERK) and MEK and subsequent phosphorylation of their substrates
was assessed essentially as follows. Recombinant proteins were diluted
in reaction buﬀer containing 20 mM MOPS (pH 7.2), 25 mM b-
glycerol phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, and
1 mM dithiothreitol. Recombinant non-activated ERK2 (0.3 lM)
added to the reaction buﬀer supplemented with ATP/MgCl2 cocktail
was used as a control. Increasing concentrations of ONOO donor
SIN-1 ranging from 10 lM to 1 mM, were added to the ERK2 and
activation reaction was performed at 30 C for 30 min. 25 lg of
MBP was then added to activated ERK2 and phosphorylation reaction
was carried out for 30 min at 30 C. The reaction was stopped by addi-
tion of 4· SDS–polyacrylamide electrophoresis reducing sample buﬀer.
For MEK2, after incubation of the enzyme with SIN-1, 0.3 lMof non-
activated ERK2 and 25 lg MBP were added to the reaction mixture
and incubated for another 30 min. Activation and phosphorylation
of ERK, MBP, and MEK was then assessed using Western immuno-
blot with respective antibodies.
2.5. Statistical analysis
The results were expressed as a fold increase from the control (non-
treated cells) and reported as the means ± S.E. Statistical signiﬁcance
was assessed by one-way ANOVA with post-hoc Dunnet test for
comparison between the groups. P < 0.05 was considered statistically
signiﬁcant.fold increase from the control (means ± S.E.) (\P < 0.05 versus
control, #P < 0.05 versus Ang II). The relative level of ERK activation
was determined by densitometric scanning of the phospho-ERK or
nitrated ERK bands and normalized to the control signal. (C)
Representative Western blots of ERK immunoprecipitated with anti-
nitrotyrosine or anti-phospho-ERK antibodies, performed with anti-
phospho-ERK and anti-nitrotyrosine antibodies, respectively, from
control cells and cells stimulated with 10 nM Ang II.3. Results
3.1. Activation and nitration of ERK1/2 by Ang II
Treatment of rat VSMC with 10 nM Ang II resulted in phos-
phorylation of ERK peaking within 5 min (2.79 ± 0.19-fold as
compared with control) and returning to the basal level after
30 min (Fig. 1A). Moreover, in Ang II treated cells, phosphor-
ylated ERK was co-immunoprecipitated with anti-nitrotyro-
sine antibody (Fig. 1B), thus providing for the ﬁrst time
evidence for the hormone-induced nitration of ERK in VSMC.
Although a substantial level of nitration was detected in con-
trol, it was slightly diminished 2 min after the treatment with
Ang II and followed by an almost immediate rebound of nitra-
tion achieving its maximal eﬀect (1.88 ± 0.12-fold as compared
with control) within 5 min and returning to the basal level after
1 h (Fig. 1B). When immunoprecipitation was performed using
either anti-nitrotyrosine or anti-phospho-ERK antibodies,
ERK nitration and phosphorylation presented essentially iden-
tical proﬁles (Fig. 1C). Since phosphorylated ERK was de-
tected in anti-nitrotyrosine immunoprecipitates, it indicates
that nitration does not target the tyrosine residue which is
being phosphorylated and that nitration and phosphorylation
are not mutually exclusive.3.2. AT1 receptor is involved in both phosphorylation and
nitration of ERK1/2
When cells were pre-incubated with the selective AT2 recep-
tor antagonist – PD123319 and then treated with Ang II, there
was no statistically signiﬁcant eﬀect on phosphorylation
(2.79 ± 0.19-fold for Ang II alone and 2.73 ± 0.15-fold for
PD123319 and Ang II) or nitration (1.88 ± 0.12-fold for Ang
II alone and 1.48 ± 0.11-fold for PD123319 and Ang II)
(Fig. 2A). Whereas treatment of VSMC with CV11974, a selec-tive AT1 receptor antagonist, completely inhibited ERK1/2
phosphorylation (2.79 ± 0.19-fold versus 1.00 ± 0.14-fold with
CV11974 and Ang II) as well as nitration (1.88 ± 0.12-fold ver-
sus 0.96 ± 0.08-fold with CV11974 and Ang II) upon Ang II
treatment (Fig. 2B).
3.3. Eﬀect of the NAD(P)H oxidase and NOS inhibitors, and
free radical scavengers on ERK1/2 tyrosine nitration and
phosphorylation
Treatment of cells with DPI and AEBSF, inhibitors of
NAD(P)H oxidase, inhibited the basal phosphorylation of
ERK in cells and subsequently completely prevented phos-
phorylation of the enzyme induced by Ang II 2- and 25-fold,
respectively, as compared with the control (Fig. 3A). Similar
results were obtained in the parallel experiments on the whole
cell lysates with anti-phospho-ERK antibody used for Western
analysis (data not shown). DPI signiﬁcantly inhibited and
AEBSF completely blocked nitration of ERK induced by
Ang II (Fig. 3B). Unlike phosphorylation, basal nitration lev-
els did not appear aﬀected by NAD(P)H oxidase inhibitors.
Similar to NAD(P)H oxidase inhibitors, preincubation of
cells with the NOS inhibitors L-NAME and 1400W, also
showed an inhibitory eﬀect on ERK phosphorylation with
1.4- and 2.7-fold inhibition for L-NAME and 1400W, respec-
tively, as compared with the Ang II (Fig. 3A). ERK nitration
was reduced 1.6-fold by L-NAME and completely blocked by
1400W (Fig. 3B).
Fig. 2. AT1 but not AT2 antagonist prevents ERK1/2 phosphoryla-
tion and nitration. Cells were preincubated for 30 min with 0.1 lM
CV11974 or 1 lM PD123319, AT1 and AT2 antagonists, respectively,
and then treated for 5 min with 10 nM Ang II. Immunoblots were
performed using (A) anti-phospho-ERK monoclonal or (B) anti-
nitrotyrosine polyclonal antibodies. Bar graphs represent the average
values (means ± S.E.) of ERK activation or nitration of four exper-
iments normalized to the control signal; \P < 0.05 versus control,
#P < 0.05 versus Ang II alone.
Fig. 3. Eﬀect of antioxidants on Ang II–induced phosphorylation and
nitration of ERK1/2. VSMC were pretreated with the NAD(P)H
oxidase inhibitors, DPI (10 lM) for 30 min or AEBSF (0.5 mM) for
1 h, with the non-selective NOS inhibitor L-NAME (50 lM) for 30 min
or the selective iNOS inhibitor 1400W (10 lM) for 1 h, and with
ebselen (50 lM) or myricetin (100 lM), ONOO and O2 scavengers,
respectively, for 30 min, prior to treatment with 10 nM Ang II for
5 min. Western blots were probed for phospho-ERK (A) and
nitrotyrosine (B). (Bar graphs) Data are representatives of four
independent experiments. Western blot results were quantitated by
densitometric scanning and expressed as means ± S.E. normalized to
the control (\P < 0.05 versus control, #P < 0.05 versus Ang II).
Fig. 4. The MEK-inhibitor U0126 completely abolishes ERK1/2
phosphorylation but not nitration. VSMC were pretreated for
30 min with 10 lM U0126, a selective MEK inhibitor, prior to the
addition of 10 nM Ang II. After 5 min of treatment with Ang II,
soluble lysates from growth arrested cells were immunoprecipitated
with anti-ERK antibodies and Western blot analysis (shown in upper
panels) was then performed with anti-phospho-ERK antibodies (A)
and anti-nitrotyrosine antibodies (B).
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reduced both nitration and phosphorylation of ERK, we
examined the sensitivity of ERK nitration and phosphoryla-
tion to reactive oxygen and nitrogen species. ONOO quen-
cher ebselen decreased ERK phosphorylation 1.7-fold as
compared to the Ang II alone (Fig. 3A). Myricetin, a highly
eﬀective scavenger of O2 , also blocked Ang II-induced ERK
phosphorylation and to a higher extent than that of ebselen
(2.3-fold as compared to Ang II) (Fig. 3A). Ebselen signiﬁ-
cantly decreased ERK nitration and myricetin completely
blocked tyrosine nitration of the enzyme as shown in Fig. 3B.
3.4. Ang II-induced ERK1/2 nitration does not require MEK
Because MEK is an upstream regulator of ERK1/2, we
investigated whether Ang II-induced nitration is dependent
on MEK. U0126, a selective MEK inhibitor, added to cells
prior to treatment with Ang II, caused a complete inhibition
of ERK phosphorylation thus preventing Ang II-induced
phosphorylation of the enzyme (Fig. 4). However, preincuba-
tion of cells with U0126 showed only an insigniﬁcant decrease
in ERK nitration (Fig. 4).
3.5. Nitration and phosphorylation of recombinant ERK by the
ONOO donor, SIN-1
To further characterize the mechanism of ERK nitration, we
treated recombinant non-activated ERK2 with the ONOO
donor, SIN-1. SIN-1 releases simultaneously NO and O2 thusforming ONOO. It has been shown that ONOO thus pro-
duced activates ERK in epithelial cells [15]. ONOO has also
been reported to induce phosphorylation and nitration of re-
combinant non-active GST – MEK1 in vitro [16]. To test
whether SIN-1 can react directly with MAPKs and whether
nitration is suﬃcient to activate kinases, we incubated either
Fig. 5. The ONOO donor, SIN-1, activates and nitrates non-
activated recombinant ERK and MEK. (A) Non-activated ERK2
was pretreated for 30 min with SIN-1 (1 mM, 100 lM, 10 lM) and
then incubated for 30 min at 30 C with its substrate – MBP. Active
ERK with MBP was loaded as positive control. (B). Non-activated
MEK2 after addition of SIN-1 (1 mM, 100 lM, 10 lM) was incubated
for 30 min at 30 C in the presence of ATP. Active MEK was loaded as
positive control. After treatment of non-activated MEK2 with SIN-1,
0.3 lM of non-activated ERK2 and 25 lg of MBP were added to
nitrated MEK and ERK activation reaction was carried our at 30 C
for 30 min. Immunoblottings were performed using indicated anti-
bodies.
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non-activated MEK2 (Fig. 5B) with diﬀerent concentrations
of SIN-1 and ATP. Addition of SIN-1 led to an increase in
either ERK2 or MEK2 nitration levels, in a concentration-
dependent manner (Fig. 5A and B). We also observed that
incubation with SIN-1 led to autophosphorylation of these ki-
nases, again in a concentration-dependent manner (Fig. 5A
and B). The non-stimulated recombinant proteins were not
able to autophosphorylate or phosphorylate their substrate
(data not shown). To test the catalytic activity of ERK and
MEK we nitrated non-activated ERK2 (Fig. 5A) and MEK2
(Fig. 5B) with SIN-1. Thus nitrated enzymes were further incu-
bated with either the ERK substrate MBP or with the MEK2
substrate non-activated ERK2 and MBP. As a result, nitrated
ERK2 and MEK2 were both catalytically active as demon-
strate the subsequent activation and phosphorylation of their
respective substrates (Fig. 5). Pretreatment of active MEK
with SIN-1 had no eﬀect on its capacity to activate ERK (data
not shown).4. Discussion
In this paper, we have investigated the link between the
observations that ERK is activated by reactive oxygen and
nitrogen species, including ONOO, and that Ang II induces
the production of these reactive oxides. The data presented
here demonstrate, for the ﬁrst time, that Ang II induces nitra-
tion as well as phosphorylation of ERK. Nitration of tyrosineresidues of proteins may alter phosphotyrosine-dependent
signaling, either positively or negatively [9]. Our data on
VSMC show that ERK1/2 nitration induced by Ang II is
accompanied by a strong activation of the enzyme (Fig. 1).
Moreover, phospho-ERK1/2 and ERK1/2 from VSMC could
be immunoprecipitated with anti-nitrotyrosine antibody,
showing that phosphorylation and nitration are not exclusion-
ary, suggesting that sites are diﬀerentially located and opens
the possibility that Ang II-induced nitration could actually
directly induce activation by triggering ERK autophosphory-
lation. This model is supported by the data on recombinant
enzymes indicating that nitration of recombinant non-
activated ERK or MEK by the ONOO donor SIN-1 results
in strong autophosphorylation and activation of the enzymes
(Fig. 5A and B). The activation of MEK by nitration
(Fig. 5B) concurs with previous ﬁndings showing recombinant
MEK autophosphorylation upon treatment with ONOO in
an in vitro model [16] and suggests that nitration may be acti-
vating multiple kinases on the same pathway. A number of
studies supports our ﬁndings that tyrosine nitration of
ERK1/2 is associated with its activation. In several cell lines
nitration of ERK by ONOO appeared to activate the enzyme
either directly or through EGFR phosphorylation or through
direct activation of Raf and MEK [14–16].
Ang II exerts multiple eﬀects on VSMC via AT1 subtype
receptors that are linked to ERK-dependent pathways and
inhibition of AT1 receptor has been shown to prevent ERK
phosphorylation [1,2]. Accordingly, ERK phosphorylation
was inhibited when VSMC were pretreated with an AT1 antag-
onist (Fig. 2). Similarly, we found that nitration of ERK1/2
was also mediated by AT1 and not AT2 receptors.
It is well documented that Ang II induces production of
ROS by inducing NAD(P)H oxidase in VSMC [3,4] and also
stimulates production of NO and ONOO [5] by iNOS [6].
Protein tyrosine nitration is considered a consequence of the
generation of reactive nitrogen oxides in cells. ROS, in turn,
were shown to play a role in nitration in VSMC [18]. As evi-
denced by the inhibitory studies with inhibitors of NAD(P)H
oxidase and iNOS and with the ONOO and O2 scavengers
(Fig. 3B), the mechanism of ERK1/2 nitration upon Ang II
stimulation is redox-sensitive and requires both NAD(P)H oxi-
dase and iNOS. Ang II-stimulated phosphorylation of ERK1/
2 in our experiments was also redox-dependent (Fig. 3A).
Reactive oxygen sensitivity of ERK1/2 is controversial and ap-
pears to vary on cell type, model used, speciﬁc experimental or
other conditions that have yet to be understood [3,4,16,19,20].
Despite the existing discrepancy on the redox sensitivity of
ERK in previous studies, the results on nitration and phos-
phorylation of ERK in VSMC combined with the data ob-
tained in an in vitro model clearly show that, under our
experimental conditions, both nitration and phosphorylation
of ERK depend on NAD(P)H oxidase and iNOS activation.
MEK, an upstream regulator of ERK, plays an important
role in ERK activation upon Ang II stimulation [1]. Moreover,
activation of ERK by ONOO is dependent on MEK activa-
tion [15,16]. Using the speciﬁc MEK inhibitor U0126, we
showed that MEK is absolutely required for Ang II-stimulated
ERK phosphorylation but not for its nitration (Fig. 4). The
diﬀerential eﬀect of MEK inhibition on phosphorylation and
nitration suggests that prior phosphorylation of ERK is not re-
quired for nitration to occur. As indicated by our results and
that of others [16], recombinant MEK is nitrated by ONOO
5104 E. Pinzar et al. / FEBS Letters 579 (2005) 5100–5104and the ONOO donor SIN-1, suggesting that formation of
nitrotyrosine activates MEK. It remains, however, unclear
whether MEK is nitrated by treatment with Ang II and if this
nitration is required for activation and/or nitration of ERK in
VSMC.
In conclusion, we demonstrated tyrosine nitration of
ERK1/2 upon Ang II stimulation in rat VSMC. Based on
our ﬁndings, it is likely that, Ang II, via activation of the
AT1 receptor, induces the production of reactive oxygen
and nitrogen species with subsequent formation of ONOO.
ONOO, in turn, nitrates tyrosine residues of ERK1/2, thus
facilitating activating phosphorylation. In parallel with the
induction of redox-sensitive pathway that contributes to
nitration and activation of ERK, Ang II also activates the
Raf–MEK–ERK pathway, which is required for ERK phos-
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